Evaluating Anti-CD20 Therapy in Pregnancy for Multiple Sclerosis

Managing family planning in women with relapsing-remitting multiple sclerosis requires balancing maternal disease stability against potential fetal drug exposure. Consequently, the safety and clinical efficacy of anti-CD20 therapy in pregnancy have become central considerations for modern neurology teams. Neurologists frequently prescribe anti-CD20 monoclonal antibodies, particularly ocrelizumab and rituximab, to achieve robust relapse suppression. However, historic protocols mandated prolonged preconception washout intervals to prevent transplacental antibody passage. Unfortunately, prolonged treatment suspension often raises serious concerns regarding rebound disease activity and disabling relapses during gestation.

Recent evidence from dedicated clinical registries provides critical reassurance regarding these concerns. In particular, real-world data indicate that therapeutic B-cell depletion maintains prolonged immunomodulatory effects long after drug discontinuation. Therefore, women often retain durable disease control throughout pregnancy without needing active infusions. Furthermore, avoiding disease reactivation remains vital for long-term functional independence. This landmark investigation clarifies how preconception infusion timing and cumulative dosing shape maternal neurological outcomes during gestation and postpartum.

Study Cohort and Registry Methodology

Researchers conducted this observational cohort study utilizing comprehensive clinical data from the German Multiple Sclerosis and Pregnancy Registry. Specifically, investigators identified women with relapsing-remitting multiple sclerosis who received ocrelizumab or rituximab prior to conception. The investigative team analyzed these prospectively recorded pregnancies to evaluate maternal annualized relapse rates and disability changes. Additionally, they stratified patients based on the exact timing of their final infusion relative to conception. This stratification permitted direct comparisons between shorter and longer pre-pregnancy drug suspensions.

Moreover, the researchers examined cumulative medication exposure and total infusions administered before treatment suspension. They tracked maternal outcomes through standardized questionnaires and neurologist clinical records across all trimesters and the postpartum year. Consequently, the methodology ensured accurate data capture regarding gestational duration, pregnancy outcomes, and maternal relapse trajectories. Furthermore, prospective registry tracking significantly reduced recall bias and missing clinical documentation. Neurologists and obstetricians can therefore interpret these findings as robust real-world evidence for clinical family planning.

Maternal Relapse Rates and Disease Activity Findings

The study demonstrated remarkably low maternal relapse activity throughout gestation. Specifically, annualized relapse rates remained consistently suppressed across all three trimesters among patients previously treated with anti-CD20 therapy. Expectant mothers overwhelmingly maintained disease stability without experiencing sudden neurological relapses or requiring rescue pulse corticosteroids. Thus, prior B-cell depletion provided durable biological protection that persisted throughout pregnancy. This enduring stability reassures clinicians who previously feared early rebound disease activity following therapy interruption.

Additionally, postpartum disease activity remained surprisingly low compared to historical cohorts. Although the immediate postpartum period carries substantial relapse vulnerability due to rapid hormonal shifts, women treated with anti-CD20 therapy experienced remarkably few attacks. Furthermore, severe disabling relapses rarely occurred in this cohort after delivery. Consequently, pre-pregnancy ocrelizumab and rituximab created a sustained protective shield that spanned the entire perinatal period. These findings confirm that pre-pregnancy treatment effectively buffers against both gestational and postpartum clinical exacerbations.

Impact of Washout Duration and Cumulative Dosing

A central objective of this registry analysis involved examining how preconception washout duration influences maternal disease recurrence. Interestingly, extending the washout period beyond six months did not offer additional maternal or fetal benefits. Conversely, prolonged treatment interruptions allowed gradual B-cell repopulation, which slightly increased maternal relapse risk before and during pregnancy. Women who conceived closer to their last infusion maintained superior clinical stability without exhibiting higher rates of gestational complications. Therefore, enforcing excessively prolonged washout periods may unnecessarily expose patients to disease reactivation.

Furthermore, the researchers analyzed whether cumulative pre-pregnancy dosing shaped long-term clinical protection. Notably, patients who received higher cumulative doses or longer continuous treatment prior to conception maintained deeper disease control. Profound B-cell depletion before pregnancy appeared to delay biological reconstitution, thereby preventing inflammatory breakthrough. Thus, establishing robust disease suppression before conception remains paramount for successful family planning. Clinicians should prioritize comprehensive disease control before conception rather than abbreviating treatment cycles prematurely.

Clinical Implications for Practice and Family Planning

These registry findings deliver essential practical guidance for neurologists and obstetricians counseling women of childbearing potential. Historically, many women with multiple sclerosis delayed or avoided pregnancy due to valid concerns about disabling relapses. However, these data confirm that preconception anti-CD20 therapy provides sustained disease protection through pregnancy and the early postpartum months. Clinicians can confidently assure prospective mothers that stopping ocrelizumab or rituximab close to conception does not trigger dangerous rebound activity. Therefore, physicians can tailor family planning decisions to individual patient readiness rather than arbitrary washout timelines.

Additionally, clinical teams must coordinate proactive postpartum care to prevent late disease recurrence. Because B-cell reconstitution eventually occurs after delivery, clinicians should arrange timely therapy resumption. Fortunately, monoclonal antibodies exhibit minimal excretion into mature breast milk, and infant digestion largely neutralizes ingested proteins. Consequently, mothers can safely breastfeed their infants while scheduling their next therapeutic infusion. In summary, multidisciplinary collaboration between neurologists and obstetricians ensures excellent maternal neurological stability and optimal infant safety.

Frequently Asked Questions

How does anti-CD20 therapy affect multiple sclerosis relapses during pregnancy?

Patients receiving anti-CD20 therapy before pregnancy typically experience exceptionally low relapse rates throughout gestation. Because monoclonal antibodies like ocrelizumab and rituximab produce sustained B-cell depletion, their protective immunomodulatory benefits persist for several months after the last infusion. Consequently, women maintain neurological stability across all three trimesters. The profound biological suppression established before conception prevents the early gestational relapses that frequently occur when stopping other disease-modifying therapies.

Is an extended preconception washout period necessary for ocrelizumab or rituximab?

Current evidence indicates that extended preconception washout intervals are generally unnecessary and may increase relapse risk. Monoclonal antibodies do not cross the placenta during the first trimester because active IgG transport begins only after sixteen weeks of gestation. Furthermore, prolonged drug-free intervals allow B-cell repopulation, which heightens the probability of disease reactivation before conception. Clinicians increasingly recommend shorter washout periods to ensure maternal stability while safeguarding fetal development.

When should patients resume anti-CD20 therapy after delivery?

Neurologists typically recommend resuming anti-CD20 therapy within several weeks to months following delivery, depending on individual maternal risk factors. Because postpartum immune shifts and B-cell repopulation heighten relapse vulnerability, prompt resumption maintains remission. Additionally, monoclonal antibodies show negligible penetration into mature breast milk, and infant gastrointestinal enzymes rapidly degrade swallowed immunoglobulins. Therefore, mothers can safely resume treatment while continuing breastfeeding, provided the clinical team monitors maternal and infant health collaboratively.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Bast N et al. Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2026 Nov undefined. doi: 10.1212/NXI.0000000000200670. PMID: 42854176.


2. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidance. Pract Neurol. 2019;19(2):106-114.


3. Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years. Lancet Neurol. 2014;13(6):627-638.